FibroBiologics, Inc. — Q1 2024 Form 10-Q
Business context and reporting period
Unaudited results cover the three months ended March 31, 2024; balance-sheet amounts are as of March 31, 2024, with December 31, 2023 comparatives. FibroBiologics is an early-stage cell-therapy company developing fibroblast-based treatments. It has no product revenue. On January 31, 2024, it completed a Nasdaq direct listing; preferred and non-voting shares largely converted into voting common stock.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $0.960 million | $0.478 million |
| General, administrative and other expense | $2.490 million | $1.787 million |
| Total operating expenses / operating loss | $3.450 million / ($3.450 million) | $2.265 million / ($2.265 million) |
| Net loss | ($8.460 million) | ($2.415 million) |
| Net loss per share | ($0.27) | ($0.18) |
| Operating cash used | $4.275 million | $2.036 million |
| Cash and cash equivalents | $8.158 million | $9.163 million at Dec. 31, 2023 |
| Total assets / total liabilities | $11.399 million / $15.262 million | $11.821 million / $10.568 million at Dec. 31, 2023 |
Current assets were $8.922 million and current liabilities $13.985 million, a $5.063 million working-capital deficit. Stockholders’ deficit was $3.863 million. Cash flow from investing was ($0.008 million); financing provided $3.278 million, including $2.819 million net common-stock proceeds under the GEM agreement. Cash declined $1.005 million during the quarter. The balance sheet reports a $0.459 million short-term note payable; management’s statement that there was no outstanding debt appears to refer to other debt, and the filing does not clearly reconcile the wording.
No meaningful margin analysis applies because the company reported no revenue. The filing does not provide a specific cash-runway estimate.
Material changes versus the prior comparable period
- Net loss increased by $6.045 million year over year. Operating expenses rose $1.185 million: R&D increased $0.482 million, primarily from added research staff, supplies and tissue acquisition; G&A increased $0.703 million, with direct-listing-related costs a major driver.
- Q1 2024 included a $3.104 million noncash loss from remeasuring the GEM warrant liability and $1.941 million of commitment-fee expense. Neither was reported in Q1 2023. These items account for much of the increase in net loss beyond higher operating expenses.
- Operating cash use more than doubled year over year. Financing inflows were far lower than Q1 2023, when the company received substantial preferred-stock proceeds.
- The direct listing triggered conversion of outstanding Series B, Series B-1 and non-voting common shares into voting common shares; Series A preferred shares were canceled for no consideration. At March 31, 32,719,125 common shares were outstanding.
Outlook, commentary, risks and unusual items
- Funding and going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern for one year from issuance of the financial statements. It expects continued losses and negative operating cash flow and says additional capital is necessary; financing may not be available on acceptable terms or at all. The financial statements contain no going-concern adjustments.
- Development plans: The company expects to complete remaining CYWC628 wound-healing preclinical studies in Q3 2024 and plans a Phase 1/2 trial in Australia in 2025, subject to funding. It expects trial results in Q3 2025. CYMS101 has completed a five-participant Phase 1 study in Mexico; a Phase 2 IND filing is anticipated as funding allows, and management may seek a strategic partner. CybroCell has FDA IND clearance conditional on master cell bank approval; timing remains to be determined with the FDA and is funding-dependent.
- Manufacturing: The company plans a technology transfer to a contract manufacturer and aims to produce master and working cell banks and clinical drug product by year-end 2024. It relies on third-party manufacturing and research organizations.
- GEM agreement and potential dilution: Q1 share sales to GEM generated $2.819 million net proceeds. The company issued GEM’s affiliate a five-year warrant for 1,299,783 shares; the warrant liability was $10.340 million at quarter-end and is subject to recurring fair-value remeasurement. Further GEM drawdowns are possible under the agreement, whose pricing and availability are subject to contractual conditions. A $2.000 million commitment fee is payable under the agreement.
- Clinical and operating risks: Product candidates remain in preclinical or early clinical development; approval, trial outcomes, manufacturing, regulatory timing, intellectual-property protection, competition and access to capital are uncertain. The company has no approved products and may never generate revenue or achieve profitability.
- Controls and legal matters: Management concluded disclosure controls were not effective because of a material weakness in segregation of duties arising from limited staffing. It plans to add staff and improve controls. The company reports no current legal proceedings.
Important facts for investors to verify
- Whether the company can raise sufficient capital, and how long its cash will support planned research and operations.
- The nature and repayment terms of the $0.459 million short-term note, and the reconciliation with management’s statement that there was no outstanding debt.
- The GEM facility’s remaining availability, commitment-fee payment timing, warrant terms and potential dilution from future share sales or warrant exercise.
- Progress and timing of CYWC628 preclinical work, planned trials, CYMS101 regulatory steps, and the CDMO manufacturing milestones; each is funding- and execution-dependent.
- Remediation of the segregation-of-duties material weakness and whether disclosure controls become effective.